People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nexosome Oncology Holdings, Inc. | — | Pharma | Seed | $3.7M | $68.9M | 2021 |
| NX Pharmagen Inc. | — | Biotechnology | Seed | $3.3M | $7.4M | 2020 |
| NX Development Corp. | — | Biotechnology | Seed | $2.5M | $31.1M | 2016 |
Alan Ezrin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alan Ezrin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Saunders | 3 | 18 |
| Brian Brohman | 3 | 4 |
| Fred Mermelstein | 2 | 3 |
| Alan M. Ezrin | 2 | 2 |
| Gregory Murdock | 1 | 3 |
| Todd Hembrough | 1 | 2 |
| Robert M. Saunders | 1 | 2 |
| Matthew Dicken | 1 | 2 |
| Cedric M. Francois | 1 | 1 |
| Pascal M. Deschatelets | 1 | 1 |
| Brian D. Brohman | 1 | 1 |
| Fred M. Mermelstein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.